Christoph Kessel1, Angela McArdle2, Emely Verweyen1, Toni Weinhage1, Helmut Wittkowski1, Stephen R Pennington2, Dirk Foell3. 1. Department of Paediatric Rheumatology and Immunology, University of Muenster, Domagkstraße 3, 48149, Muenster, Germany. 2. UCD Conway Institute of Biomolecular and Biomedical Research, School of Medicine, University College Dublin, Dublin, Ireland. 3. Department of Paediatric Rheumatology and Immunology, University of Muenster, Domagkstraße 3, 48149, Muenster, Germany. dfoell@uni-muenster.de.
Abstract
PURPOSE OF REVIEW: Current technical advances enable the assessment of the complex changes in body fluid proteomes and thus allow for the discovery of biomarker signatures rather than just following differences of a single marker. In this review, we aim to summarize current approaches to discover and evaluate multi-biomarker panels for improved monitoring of chronic arthritis disease activity. RECENT FINDINGS: Mass spectrometry and affinity proteomic methodologies have been used to identify biomarker panels in synovial fluid, serum, plasma, or urine of pediatric and adult chronic arthritis patients. Notably, despite the numerous efforts to develop new and better biomarker panels, very few have undergone extensive analytical and clinical validation and been adopted into routine use for patient benefit. There remains a significant gap between discovery of chronic arthritis biomarker signatures and their validation for clinical use.
PURPOSE OF REVIEW: Current technical advances enable the assessment of the complex changes in body fluid proteomes and thus allow for the discovery of biomarker signatures rather than just following differences of a single marker. In this review, we aim to summarize current approaches to discover and evaluate multi-biomarker panels for improved monitoring of chronic arthritis disease activity. RECENT FINDINGS: Mass spectrometry and affinity proteomic methodologies have been used to identify biomarker panels in synovial fluid, serum, plasma, or urine of pediatric and adult chronic arthritispatients. Notably, despite the numerous efforts to develop new and better biomarker panels, very few have undergone extensive analytical and clinical validation and been adopted into routine use for patient benefit. There remains a significant gap between discovery of chronic arthritis biomarker signatures and their validation for clinical use.
Authors: André M N Silva; Rui Vitorino; M Rosário M Domingues; Corinne M Spickett; Pedro Domingues Journal: Free Radic Biol Med Date: 2013-08-31 Impact factor: 7.376
Authors: Wilco de Jager; Esther P A H Hoppenreijs; Nico M Wulffraat; Lucy R Wedderburn; Wietse Kuis; Berent J Prakken Journal: Ann Rheum Dis Date: 2006-12-14 Impact factor: 19.103
Authors: Ben C Collins; Christine A Miller; Alexandra Sposny; Phillip Hewitt; Martin Wells; William M Gallagher; Stephen R Pennington Journal: Mol Cell Proteomics Date: 2012-04-23 Impact factor: 5.911
Authors: Xuefeng B Ling; Kenneth Lau; Chetan Deshpande; Jane L Park; Diana Milojevic; Claudia Macaubas; Chris Xiao; Viorica Lopez-Avila; John Kanegaye; Jane C Burns; Harvey Cohen; James Schilling; Elizabeth D Mellins Journal: Clin Proteomics Date: 2010-09-30 Impact factor: 3.988
Authors: P Scott Eastman; William C Manning; Ferhan Qureshi; Douglas Haney; Guy Cavet; Claire Alexander; Lyndal K Hesterberg Journal: J Pharm Biomed Anal Date: 2012-06-12 Impact factor: 3.935
Authors: David S Gibson; Madeleine E Rooney; Sorcha Finnegan; Ji Qiu; David C Thompson; Joshua Labaer; Stephen R Pennington; Mark W Duncan Journal: Rheumatology (Oxford) Date: 2011-12-16 Impact factor: 7.580